GCP
CCCC icon

GSA Capital Partners’s C4 Therapeutics CCCC Stock Holding History

GSA Capital Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,963
Closed -$16K – 1687
2025
Q2 		$16K Sell
10,963
-32,978
-75% -$48K ﹤0.01% 1692
2025
Q1 		$70K Buy
+43,941
New +$131K 0.01% 1532
2024
Q4 		– Sell
-15,446
Closed -$88K – 1641
2024
Q3 		$88K Sell
15,446
-7,822
-34% -$47.1K 0.01% 1502
2024
Q2 		$107K Sell
23,268
-25,495
-52% -$152K 0.01% 1525
2024
Q1 		$398K Buy
+48,763
New +$378K 0.03% 1042
2023
Q3 		– Sell
-312,135
Closed -$858K – 1526
2023
Q2 		$858K Buy
312,135
+135,084
+76% +$434K 0.09% 401
2023
Q1 		$556K Buy
177,051
+162,419
+1,110% +$956K 0.06% 643
2022
Q4 		$86K Sell
14,632
-5,273
-26% -$43.7K 0.01% 1320
2022
Q3 		$175K Sell
19,905
-2,439
-11% -$25.3K 0.02% 1265
2022
Q2 		$168K Buy
+22,344
New +$197K 0.03% 1112

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GSA Capital Partners's CCCC Position: Q3 2025 in Review

GSA Capital Partners sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 10,963 shares — an estimated $16K sold.

GSA Capital Partners first reported a position in CCCC in Q2 2022 and held it in 10 quarters. The position peaked at $858K in Q2 2023. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • GSA Capital Partners reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 10,963 C4 Therapeutics shares in Q3 2025, an estimated $16K.
  • GSA Capital Partners first reported a position in C4 Therapeutics in Q2 2022 and held it in 10 quarters.
  • GSA Capital Partners's C4 Therapeutics position peaked at $858K in Q2 2023.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.